Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation

Manuel Pascual, Ravi Thadhani, Michael Laposata, Winfred W. Williams, Mary Lin Farrell, Stephen M. Johnson, Nina Tolkoff-Rubin, A. Benedict Cosimi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background. Hepatic artery thrombosis (HAT) remains a devastating complication after liver transplantation. Various factors have been implicated in the pathogenesis of HAT, such as clotting abnormalities, increased hematocrit, and technical complications, but the role of anticardiolipin antibodies has not been evaluated. We investigated the possible association between HAT and anticardiolipin antibodies in adult patients who underwent liver transplantation. Methods. Seven patients with HAT after orthotopic liver transplantation, 28 liver recipients without HAT, and 35 normal blood donors were evaluated. Determination of IgM and IgG anticardiolipin antibodies was performed by enzyme-linked immunosorbent assay using pretransplant serum from all allograft recipients. Clinical information was obtained from chart review. Fishers exact test and Wilcoxon rank sum test were used for statistical analysis, and all P-values were two-tailed. Results. Overall, 22 of 35 (63%) liver recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >4 SD from the normal controls). The test was positive in 7 liver recipients (100%) with HAT compared with 15 out of 28 patients (54%) without HAT (P=0.031). As compared with liver recipients without HAT, patients with HAT also tended to have a higher mean anticardiolipin titer of IgG and IgM and a lower pretransplant platelet count; however, these differences were not significant. Conclusions. Our findings indicate that anticardiolipin antibodies are frequently elevated in patients with liver failure and may contribute to the pathogenesis of HAT after liver transplantation. Other potential consequences of anticardiolipin antibodies in end-stage liver disease remain to be determined.

Original languageEnglish
Pages (from-to)1361-1364
Number of pages4
JournalTransplantation
Volume64
Issue number9
DOIs
StatePublished - Nov 15 1997
Externally publishedYes

Fingerprint

Anticardiolipin Antibodies
Hepatic Artery
Liver Transplantation
Thrombosis
Immunoglobulin M
Immunoglobulin G
Liver
Nonparametric Statistics
End Stage Liver Disease
Liver Failure
Blood Donors
Platelet Count
Hematocrit
Allografts
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Pascual, M., Thadhani, R., Laposata, M., Williams, W. W., Farrell, M. L., Johnson, S. M., ... Cosimi, A. B. (1997). Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation. Transplantation, 64(9), 1361-1364. https://doi.org/10.1097/00007890-199711150-00021

Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation. / Pascual, Manuel; Thadhani, Ravi; Laposata, Michael; Williams, Winfred W.; Farrell, Mary Lin; Johnson, Stephen M.; Tolkoff-Rubin, Nina; Cosimi, A. Benedict.

In: Transplantation, Vol. 64, No. 9, 15.11.1997, p. 1361-1364.

Research output: Contribution to journalArticle

Pascual, M, Thadhani, R, Laposata, M, Williams, WW, Farrell, ML, Johnson, SM, Tolkoff-Rubin, N & Cosimi, AB 1997, 'Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation', Transplantation, vol. 64, no. 9, pp. 1361-1364. https://doi.org/10.1097/00007890-199711150-00021
Pascual, Manuel ; Thadhani, Ravi ; Laposata, Michael ; Williams, Winfred W. ; Farrell, Mary Lin ; Johnson, Stephen M. ; Tolkoff-Rubin, Nina ; Cosimi, A. Benedict. / Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation. In: Transplantation. 1997 ; Vol. 64, No. 9. pp. 1361-1364.
@article{0348094a5c9448bbb49503fd55e812d2,
title = "Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation",
abstract = "Background. Hepatic artery thrombosis (HAT) remains a devastating complication after liver transplantation. Various factors have been implicated in the pathogenesis of HAT, such as clotting abnormalities, increased hematocrit, and technical complications, but the role of anticardiolipin antibodies has not been evaluated. We investigated the possible association between HAT and anticardiolipin antibodies in adult patients who underwent liver transplantation. Methods. Seven patients with HAT after orthotopic liver transplantation, 28 liver recipients without HAT, and 35 normal blood donors were evaluated. Determination of IgM and IgG anticardiolipin antibodies was performed by enzyme-linked immunosorbent assay using pretransplant serum from all allograft recipients. Clinical information was obtained from chart review. Fishers exact test and Wilcoxon rank sum test were used for statistical analysis, and all P-values were two-tailed. Results. Overall, 22 of 35 (63{\%}) liver recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >4 SD from the normal controls). The test was positive in 7 liver recipients (100{\%}) with HAT compared with 15 out of 28 patients (54{\%}) without HAT (P=0.031). As compared with liver recipients without HAT, patients with HAT also tended to have a higher mean anticardiolipin titer of IgG and IgM and a lower pretransplant platelet count; however, these differences were not significant. Conclusions. Our findings indicate that anticardiolipin antibodies are frequently elevated in patients with liver failure and may contribute to the pathogenesis of HAT after liver transplantation. Other potential consequences of anticardiolipin antibodies in end-stage liver disease remain to be determined.",
author = "Manuel Pascual and Ravi Thadhani and Michael Laposata and Williams, {Winfred W.} and Farrell, {Mary Lin} and Johnson, {Stephen M.} and Nina Tolkoff-Rubin and Cosimi, {A. Benedict}",
year = "1997",
month = "11",
day = "15",
doi = "10.1097/00007890-199711150-00021",
language = "English",
volume = "64",
pages = "1361--1364",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation

AU - Pascual, Manuel

AU - Thadhani, Ravi

AU - Laposata, Michael

AU - Williams, Winfred W.

AU - Farrell, Mary Lin

AU - Johnson, Stephen M.

AU - Tolkoff-Rubin, Nina

AU - Cosimi, A. Benedict

PY - 1997/11/15

Y1 - 1997/11/15

N2 - Background. Hepatic artery thrombosis (HAT) remains a devastating complication after liver transplantation. Various factors have been implicated in the pathogenesis of HAT, such as clotting abnormalities, increased hematocrit, and technical complications, but the role of anticardiolipin antibodies has not been evaluated. We investigated the possible association between HAT and anticardiolipin antibodies in adult patients who underwent liver transplantation. Methods. Seven patients with HAT after orthotopic liver transplantation, 28 liver recipients without HAT, and 35 normal blood donors were evaluated. Determination of IgM and IgG anticardiolipin antibodies was performed by enzyme-linked immunosorbent assay using pretransplant serum from all allograft recipients. Clinical information was obtained from chart review. Fishers exact test and Wilcoxon rank sum test were used for statistical analysis, and all P-values were two-tailed. Results. Overall, 22 of 35 (63%) liver recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >4 SD from the normal controls). The test was positive in 7 liver recipients (100%) with HAT compared with 15 out of 28 patients (54%) without HAT (P=0.031). As compared with liver recipients without HAT, patients with HAT also tended to have a higher mean anticardiolipin titer of IgG and IgM and a lower pretransplant platelet count; however, these differences were not significant. Conclusions. Our findings indicate that anticardiolipin antibodies are frequently elevated in patients with liver failure and may contribute to the pathogenesis of HAT after liver transplantation. Other potential consequences of anticardiolipin antibodies in end-stage liver disease remain to be determined.

AB - Background. Hepatic artery thrombosis (HAT) remains a devastating complication after liver transplantation. Various factors have been implicated in the pathogenesis of HAT, such as clotting abnormalities, increased hematocrit, and technical complications, but the role of anticardiolipin antibodies has not been evaluated. We investigated the possible association between HAT and anticardiolipin antibodies in adult patients who underwent liver transplantation. Methods. Seven patients with HAT after orthotopic liver transplantation, 28 liver recipients without HAT, and 35 normal blood donors were evaluated. Determination of IgM and IgG anticardiolipin antibodies was performed by enzyme-linked immunosorbent assay using pretransplant serum from all allograft recipients. Clinical information was obtained from chart review. Fishers exact test and Wilcoxon rank sum test were used for statistical analysis, and all P-values were two-tailed. Results. Overall, 22 of 35 (63%) liver recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >4 SD from the normal controls). The test was positive in 7 liver recipients (100%) with HAT compared with 15 out of 28 patients (54%) without HAT (P=0.031). As compared with liver recipients without HAT, patients with HAT also tended to have a higher mean anticardiolipin titer of IgG and IgM and a lower pretransplant platelet count; however, these differences were not significant. Conclusions. Our findings indicate that anticardiolipin antibodies are frequently elevated in patients with liver failure and may contribute to the pathogenesis of HAT after liver transplantation. Other potential consequences of anticardiolipin antibodies in end-stage liver disease remain to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0030712342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030712342&partnerID=8YFLogxK

U2 - 10.1097/00007890-199711150-00021

DO - 10.1097/00007890-199711150-00021

M3 - Article

C2 - 9371681

AN - SCOPUS:0030712342

VL - 64

SP - 1361

EP - 1364

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -